Small studies have shown that fully vaccinated immunocompromised people account for ~44 percent of breakthrough cases leading to hospitalization
WEDNESDAY, Oct. 27, 2021 (HealthDay News) — Severely immunocompromised people may require a fourth mRNA COVID-19 shot, the U.S. Centers for Disease Control and Prevention says. The agency did not provide an official recommendation about a fourth shot in its updated guidelines but did say that people should talk to their doctors to determine if one is necessary, CNN reported.
In August, the CDC authorized a third dose for certain immunocompromised people ages 18 years and older who may not have a complete immune response from the first two doses. The U.S. Food and Drug Administration has approved booster shots of all three available vaccines in the United States for certain people, including those with compromised immune systems.
According to the CDC, small studies have shown that fully vaccinated immunocompromised people accounted for about 44 percent of the breakthrough cases that led to hospitalization. And one Johns Hopkins University study showed that vaccinated immunocompromised people were 485 times more likely than most vaccinated people to be hospitalized with COVID-19 or die from the disease, CNN reported. Research shows that a booster shot improves the antibody response to the vaccine in certain immunocompromised people.
People who are immunocompromised who got the single-dose Johnson & Johnson shot should get a booster at least two months after their initial vaccine. People who choose a Moderna vaccine as a booster, even if they received a different vaccine as the first dose, should get the half-dose sized shot that was authorized as a booster for the Moderna vaccine, the CDC said in its recommendations. Even if they are vaccinated, the CDC recommends people with conditions that compromise their immune systems should still try to avoid crowds and poorly ventilated spaces and should wear a mask in indoor public spaces.
CNN Article
Copyright © 2021 HealthDay. All rights reserved.
